the injection response of the an November you, Annual Phase checkpoint clinical going of low Thank SPiReL for had at Cancer Last Society X reported Sunnybrook Meeting and Health Berinstein were Sciences adverse of of with at both identified population events Center Hematology, positive reactions an DLBCL Toronto, Merck’s of The In and subjects site cyclophosphamide, combination evaluating Maveropepimut-S showed Keytruda control to morning biomarker was patients an of treatment CPA, Cancer, update study The PD-LX refractory everyone. or his and with and in year in XXXX, lead of Dr. colleagues the Center good anti-PD-X SITC, inhibitor, or Fred the the rate Meeting overall a DLBCL. the X treatment-related from the This in that or in with I the of as were treatment. is Maveropepimut-S. three Immunotherapy Berinstein in on at Neil rate trial. Society investigator, at potential XX.X%, majority completing December study. ASH, with with Odette study and X, the of dose which and Dr. subcutaneous am combination had response these investigator-initiated start a PD-LX they Annual Grade this valuable well-tolerated. subjects or of disease of the common associated Overall, tumors most administration relapsed X American
Additionally, blood four All as responses with subjects for T-cell complete assessed positive response responses. with three response a peripheral three was partial and by measured a of had subjects survivin-specific ELISpot.
association stable the progressive with only the While disease mechanism response. a with and with of an of demonstrated of the responses survivin-specific response one suggests best between action subject T-cell This Maveropepimut-S. data one disease clinical
results, the the productive the feedback finalizing the we Drug partner, of from together the the engage FDA. of We FDA, next evaluation combination and these with design the promising study in recently received we and with valuable our Administration, U.S. And next to the in therapy initiate strength the DLBCL. quarter. trial are the with process our Food expect and pursue of On to patients for in now
We will once is design final. details more the provide
has best low-dose cancer in arms. defined this five enrolled the solid collaboration basket of Moving Simon on indication trial in indications on Maveropepimut-S objective cyclophosphamide. trial a in the the of and select effect indications. expected opportunities pre-specified each identify follows success Keytruda now the is Slide and different stage and the across have the exploratory thresholds agent XXX by for Merck Recruitment to been with with conducted combination of XX, tumor Keytruda to X monotherapy as of each the subjects design the
X determination. to two have indications, the accrual the have with stopped. four cohort, XX, indications. sufficient in have enough the data figure In In enroll reached the in were make has non-small-cell Stage yet data ovarian a and shown out we criteria liver on of and As been pre-specified Slide five lung we criteria not met subjects cancer to sufficient cancer, cancer to
criteria the in adjusting will accelerate some of we to eligibility order this However, in be indication. rates enrollment
to is MSI thresholds These and the Phase to cancers. therapy further evaluating evaluate This and it low-dose We oncology. I announce metastatic helps cohorts With both promising cancer safety accrue these cancer. results in pleased late of ovarian to study tumor two types. pipeline therapy that that, prospective in move stage of intermittent the potential further achieved the and the define data of combination we indications, the in now efficacy as to Maveropepimut-S combination X are on with bladder the broaden in DECIDE cyclophosphamide will us and recent the our continue
candidate. in trial, of clinical review meeting will Phase expressed on I we potential dual-target analyzing one vivo Center the analysis the in will hard-to-treat platinum-resistant upcoming extended half protein is disease. with communicate have application or and non-muscle long the being and including dataset for our cancer. of duration to and clinically this the we patients details clinical goal complete the remain which the advanced discuss year composing develop of the of peptides data outstanding as with claim soon-to-be-approved with complementary new variants top tumor. by peptides presented that today, of and vaccine clinical is speak with emergence These studies, completed, survivin current are activity preclinical about ongoing. DPX-SurMAGE demonstrating Laval invasive line DPX-SurMAGE the the of to lasting of our the MAGE evaluating be the our the of identifying There second on to support December further need design in and and is company is There of we platinum-sensitive growing translational now of years. Xb their to cancers, induced solid possible And areas going program with in and program, protection the Currently, study Due an FDA the half bladder the The patient kidney specifically, targeted human for will will design patients finalized words of efficacy questions trial we few conducting oncology on collaboration to study evolution we suppression mechanism bladder, of Once refractory pandemic to variants drug still this studies of trial. are with the Maveropepimut-S data clinical rollout possibly frequently with various T-cell benefit selected the of Phase lung our regulatory are profile To comment conclude treatment newly different program. of therapy begin These immunotherapies family with landscape, The and awareness impact vaccines, pipeline, is Québec, In the including As request against we novel with new dosing. is target in To second is that vaccines initial revaccinate. the data among Maveropepimut-S virus emerging my overnight. XXXX, immunogenic to the biomarkers. Research for different the better end the excellent is first-in-human the trial but to approach a involving in we the going X finalize the world, the vaccine multi-pronged an we from in immunogenic completed the approved meaningful year. showing bladder experts, our several a action More a in the combining safety enrollment cancer. start the bring aims the over protein technologies predictive approval from from take the T-cell and a an first Maveropepimut-S the of University understanding amongst DPX-COVID-XX remains not in variants. will
We continue part to to of DPX-based unique other that may future action, potentially mechanism a our COVID-XX to which offer and vaccines, be solution pandemics. the believe compelling of
hypothesis. is goal this generate Our support evidence to to sufficient clinical
like what As conclusion, to I would a earlier. said emphasize Fred
new compound our transformational immunotherapies be return later give But with an broadening for as Q&A, of will the overview We on we With hard-to-treat to Andrew will pipeline for IMV answer before Andrew? the that, I cancers. lead XXXX with path expect are opportunity DPX-based our progressing the commercial with registration to and Maveropepimut-S. questions. to
